SCHEMBL30141882

SCHEMBL30141882

CC(C)(COc1ccc2c(C#N)cnn2c1)O[Si](C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 20/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23929885 0.84 RET (0.51) RET
Hydrochloric Acid SCHEMBL29615025 0.83 RET (0.50) RET
Hydrochloric Acid SCHEMBL30363115 0.83 RET (0.50) RET
SCHEMBL31298400 0.80 RET (0.42) RET
SCHEMBL29566683 0.79 RET (0.45) RET
Hydrochloric Acid SCHEMBL28993707 0.78 RET (0.44) RET
SCHEMBL30175335 0.77 RET (0.37) RET
SCHEMBL30175294 0.77 RET (0.43) RET
SCHEMBL25252185 0.77 CDK2 (0.36) RET
SCHEMBL30175370 0.77 CDK2 (0.36) RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4136090-A1 CRYSTALLINE RET INHIBITOR Loxo Oncology, Inc. (US) 2023-02-22 — — EP claimed
EP-4136090-A1 CRYSTALLINE RET INHIBITOR Loxo Oncology, Inc. (US) 2023-02-22 — — EP disclosed
Send feedback